Market Cap 1.14B
Revenue (ttm) 332.07M
Net Income (ttm) 18.25M
EPS (ttm) N/A
PE Ratio 156.40
Forward PE N/A
Profit Margin 5.50%
Debt to Equity Ratio 0.02
Volume 438,400
Avg Vol 396,342
Day's Range N/A - N/A
Shares Out 29.19M
Stochastic %K 81%
Beta 1.14
Analysts Strong Sell
Price Target $37.25

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 866 788 9007
Address:
505 S. Friendswood Drive, Suite 401, Friendswood, United States
Dream2121
Dream2121 Dec. 4 at 2:10 AM
$CSTL $70 by 3rd Q 2026
0 · Reply
BioTechNoir
BioTechNoir Nov. 25 at 5:45 PM
$CSTL go baby
0 · Reply
Dream2121
Dream2121 Nov. 23 at 3:54 PM
0 · Reply
BioTechNoir
BioTechNoir Nov. 21 at 3:56 PM
$CSTL 52 week high!
0 · Reply
Dream2121
Dream2121 Nov. 21 at 1:03 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 7:54 AM
$CSTL Outstanding article that hits the mark on CSTL's current state. So if you want to refresh your CSTL insights or learn about CSTL from scratch, this is a must read. https://beyondspx.com/quote/CSTL/analysis/castle-biosciences-precision-diagnostics-powering-growth-amidst-reimbursement-headwinds-cstl
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 12:02 AM
0 · Reply
GREEN_IAM
GREEN_IAM Nov. 14 at 12:07 PM
$CSTL - New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node PositivitySecond study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes
0 · Reply
Leadballoon
Leadballoon Nov. 8 at 3:15 AM
$CSTL https://www.youtube.com/watch?v=uqZZIDk2c_Y MaetSOLD curse.
0 · Reply
Leadballoon
Leadballoon Nov. 7 at 11:50 AM
$CSTL Flurries, waves, pounding of keyboards- Cramer voice SELL, SELL, SELL coming in the next week from MaetSOLD= never fails.
1 · Reply
Latest News on CSTL
Why Castle Biosciences' Rally Might Just Be Getting Started

Nov 5, 2025, 8:02 AM EST - 4 weeks ago

Why Castle Biosciences' Rally Might Just Be Getting Started


Castle Biosciences Reports Third Quarter 2025 Results

Nov 3, 2025, 4:07 PM EST - 4 weeks ago

Castle Biosciences Reports Third Quarter 2025 Results


Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:21 PM EDT - 4 months ago

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript


Castle (CSTL) Q2 Revenue Tops Estimates

Aug 4, 2025, 8:50 PM EDT - 4 months ago

Castle (CSTL) Q2 Revenue Tops Estimates


Castle Biosciences Reports Second Quarter 2025 Results

Aug 4, 2025, 4:05 PM EDT - 4 months ago

Castle Biosciences Reports Second Quarter 2025 Results


Castle Biosciences Celebrates Skin Cancer Awareness Month

May 7, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month


Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:58 PM EDT - 7 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript


Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:06 PM EDT - 7 months ago

Castle Biosciences Reports First Quarter 2025 Results


Castle Biosciences to Acquire Previse

May 5, 2025, 4:05 PM EDT - 7 months ago

Castle Biosciences to Acquire Previse


Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:09 PM EST - 10 months ago

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript


Dream2121
Dream2121 Dec. 4 at 2:10 AM
$CSTL $70 by 3rd Q 2026
0 · Reply
BioTechNoir
BioTechNoir Nov. 25 at 5:45 PM
$CSTL go baby
0 · Reply
Dream2121
Dream2121 Nov. 23 at 3:54 PM
0 · Reply
BioTechNoir
BioTechNoir Nov. 21 at 3:56 PM
$CSTL 52 week high!
0 · Reply
Dream2121
Dream2121 Nov. 21 at 1:03 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 18 at 7:54 AM
$CSTL Outstanding article that hits the mark on CSTL's current state. So if you want to refresh your CSTL insights or learn about CSTL from scratch, this is a must read. https://beyondspx.com/quote/CSTL/analysis/castle-biosciences-precision-diagnostics-powering-growth-amidst-reimbursement-headwinds-cstl
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 12:02 AM
0 · Reply
GREEN_IAM
GREEN_IAM Nov. 14 at 12:07 PM
$CSTL - New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node PositivitySecond study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomes
0 · Reply
Leadballoon
Leadballoon Nov. 8 at 3:15 AM
$CSTL https://www.youtube.com/watch?v=uqZZIDk2c_Y MaetSOLD curse.
0 · Reply
Leadballoon
Leadballoon Nov. 7 at 11:50 AM
$CSTL Flurries, waves, pounding of keyboards- Cramer voice SELL, SELL, SELL coming in the next week from MaetSOLD= never fails.
1 · Reply
BioTechNoir
BioTechNoir Nov. 5 at 5:10 PM
$CSTL RUNNER!!
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 5 at 4:01 PM
0 · Reply
JarvisFlow
JarvisFlow Nov. 5 at 9:48 AM
BTIG has adjusted their stance on Castle Biosciences ( $CSTL ), setting the rating to Buy with a target price of 32 → 38.
0 · Reply
topstockalerts
topstockalerts Nov. 4 at 7:15 PM
$CSTL strong watch at these levels
0 · Reply
topstockalerts
topstockalerts Nov. 4 at 6:41 PM
$CSTL showing high relative strength....
0 · Reply
trademaster2121
trademaster2121 Nov. 4 at 6:40 PM
$CSTL what’s the chance this hits ATH by EOY?
2 · Reply
cranio_verde
cranio_verde Nov. 4 at 6:02 PM
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 5:19 PM
Baird has adjusted their stance on Castle Biosciences ( $CSTL ), setting the rating to Outperform with a target price of 39 → 41.
0 · Reply
Okadarlan
Okadarlan Nov. 4 at 4:35 PM
$CSTL high price 34/// low price 19 ... short.
1 · Reply
IN0V8
IN0V8 Nov. 4 at 4:28 PM
$CSTL Revenues were $83 mil, compared to $85.8 million in the 3rd quarter of 24. Gross margin was 75%, and Adjusted Gross Margin was 77%, compared to 79% and 82%, respectively, for the same periods in 24. Net cash provided by operations was $22.6 million, compared to $23.3 million for the same period in 24. Net loss, which includes non-cash stock-based compensation expense of $12.1 million, was $0.5 million, compared to net income of $2.X.3 million for the same period in 24. Net loss per share and Adjusted Net Loss per Share, Basic and Diluted, was $0.02, compared to net income per share and Adjusted Net Income per Share, Basic and Diluted, of $0.08, for the same period in 24. Adjusted EBITDA was $9.2 million, compared to $21.6 million for the same period in 24.
0 · Reply
BioTechNoir
BioTechNoir Nov. 4 at 3:56 PM
$CSTL will be interested to see analyst updates on new test and financials after the call
0 · Reply
RocketThief
RocketThief Nov. 4 at 2:33 PM
$CSTL truth
0 · Reply